{"id":"NCT01217944","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","officialTitle":"A 12 Month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Different Dosing Regimens of 0.5 mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2012-08","completion":"2012-08","firstPosted":"2010-10-08","resultsPosted":"2013-10-18","lastUpdate":"2014-02-10"},"enrollment":277,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Pathological Myopia"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":[]},{"type":"DRUG","name":"Verteporfin PDT","otherNames":["vPDT"]},{"type":"DRUG","name":"Sham Ranibizumab","otherNames":[]},{"type":"DRUG","name":"Sham verteporfin PDT","otherNames":[]}],"arms":[{"label":"Ranibizumab driven by disease activity","type":"EXPERIMENTAL"},{"label":"Ranibizumab driven by stabilization criteria","type":"EXPERIMENTAL"},{"label":"Verteporfin PDT","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab given as intravitreal injection in comparison to verteporfin PDT in patients with visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (PM).","primaryOutcome":{"measure":"Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye","timeFrame":"Baseline, Month 1 through Month 3","effectByArm":[{"arm":"0.5 mg Ranibizumab Driven by Stabilization Criteria","deltaMin":55.4,"sd":13.43},{"arm":"0.5mg Ranibizumab Driven by Disease Activity","deltaMin":55.8,"sd":12.59},{"arm":"Verteporfin PDT","deltaMin":54.7,"sd":13.84}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":74,"countries":["Austria","Canada","France","Germany","Hong Kong","Hungary","India","Italy","Japan","Latvia","Lithuania","Poland","Portugal","Singapore","Slovakia","South Korea","Spain","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["25109929","24326106"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":106},"commonTop":["Nasopharyngitis","Conjunctival haemorrhage (Study eye)","Headache","Intraocular pressure increased (Study eye)","Punctate keratitis (Study eye)"]}}